B. R. Smith

发表

Inhibition of p38 mitogen‐activated protein kinase provides neuroprotection in cerebral focal ischemia

S. Kassis, John C. Lee, A. A. Parsons, 2001, Medicinal research reviews.

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

S. Kassis, John C. Lee, J. Adams, 2001, The Journal of pharmacology and experimental therapeutics.

Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

K. Ward, B. R. Smith, R. Keenan, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism and biliary excretion of benzo[a]pyrene 4,5-oxide in the rat.

J. Plummer, B. R. Smith, L. Ball, 1980, Drug metabolism and disposition: the biological fate of chemicals.

Regiospecificity and stereospecificity in the enzymatic conjugation of glutathione with (+/-)-benzo(a)pyrene 4,5-oxide.

B. R. Smith, R. Cox, J. Bend, 1980, Biochemical and Biophysical Research Communications - BBRC.

Chemical depletion of glutathione in vivo.

J. Plummer, B. R. Smith, H. Sies, 1981, Methods in enzymology.

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

K. Ward, K. Erhard, R. Calvo, 2000, Journal of medicinal chemistry.

Sea Lamprey (Petromyzon marinus) in Lakes Huron, Michigan, and Superior: History of Invasion and Control, 1936–78

B. R. Smith, J. J. Tibbles, 1980 .

Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat

K. Ward, B. R. Smith, M. Lark, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Metabolism of benzo(a)pyrene and benzo(a)pyrene 4,5-oxide in rabbit lung.

J. Plummer, C. Wolf, T. Devereux, 1981, Advances in experimental medicine and biology.

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man

K. Ward, B. R. Smith, M. Ho, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

Metabolism and radiosensitization of 4,5-dimethylmisonidazole, a ring-substituted analog of misonidazole.

C. Koch, B. R. Smith, J. Born, 1992, Biochemical pharmacology.

Phosphate Availability and Inorganic Transformation in an Alum Sludge‐Affected Soil

B. R. Smith, J. Camberato, A. Cox, 1997 .

Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics.

K. Ward, B. R. Smith, M. Levy, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Prediction of pulmonary benzo(a)pyrene 4,5-oxide clearance: a pharmacokinetic analysis of epoxide-metabolizing enzymes in rabbit lung.

B. R. Smith, J. Bend, 1980, The Journal of pharmacology and experimental therapeutics.

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Y. Ru, D. Veber, K. Erhard, 2002, Bone.

Forskolin, a potent adenylate cyclase activator, lowers rabbit intraocular pressure.

B. R. Smith, R. Gaster, I. Leopold, 1984, Archives of ophthalmology.

Concentration-dependent metabolism and toxicity of [14C] styrene oxide in the isolated perfused rat liver.

B. R. Smith, J. Bend, J. Fouts, 1979, The Journal of pharmacology and experimental therapeutics.

Estimation of the styrene 7,8-oxide-detoxifying potential of epoxide hydrolase in glutathione-depleted, perfused rat livers.

B. R. Smith, J. Bend, J. Fouts, 1983, The Journal of pharmacology and experimental therapeutics.

The metabolism and excretion of styrene oxide-glutathione conjugates in the rat and by isolated perfused liver, lung and kidney preparations.

B. R. Smith, B. Yagen, R. Cox, 1981, The Journal of pharmacology and experimental therapeutics.

p-Xylene metabolism by rabbit lung and liver and its relationship to the selective destruction of pulmonary cytochrome P-450.

J. Plummer, C. Wolf, B. R. Smith, 1982, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

L. Grochow, R. Donehower, S. Kaufmann, 1992, Drug metabolism and disposition: the biological fate of chemicals.

Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion

K. Ward, B. R. Smith, J. Kehler, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists

K. Ward, R. Willette, T. Yue, 2003 .

Influence of hypoxia on the metabolism and excretion of misonidazole by the isolated perfused rat liver--a model system.

B. R. Smith, J. Born, D. Garcia, 1983, Biochemical pharmacology.

Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution.

J. Beijnen, B. R. Smith, W. Underberg, 1990, Journal of pharmaceutical and biomedical analysis.

Lung perfusion techniques for xenobiotic metabolism and toxicity studies.

B. R. Smith, J. Bend, 1981, Methods in enzymology.

Influence of topically applied prazosin on the intraocular pressure of experimental animals.

B. R. Smith, I. Leopold, D. Murray, 1979, Archives of ophthalmology.

Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics.

B. R. Smith, R. Keenan, C. Yuan, 1999, Bioorganic & medicinal chemistry letters.

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

K. Ward, B. R. Smith, J. Mumaw, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics

K. Ward, B. R. Smith, L. M. Azzarano, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

Role of cytochrome P-450 and related enzymes in the pulmonary metabolism of xenobiotics.

B. R. Smith, R. Philpot, 1984, Environmental health perspectives.

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

S. Rodenhuis, J. Beijnen, W. W. ten Bokkel Huinink, 1990, Journal of pharmaceutical and biomedical analysis.

Metabolism and excretion of benzo(a)pyrene 4,5-oxide by the isolated perfused rat liver.

B. R. Smith, J. Bend, 1979, Cancer research.

The rabbit pulmonary monooxygenase system. Catalytic differences between two purified forms of cytochrome P-450 in the metabolism of benzo(a)pyrene.

C. Wolf, B. R. Smith, L. Ball, 1979, The Journal of biological chemistry.

Membrane receptors for polypeptide hormones.

B. R. Smith, Bernard Rees Smith, 1977, Advances in clinical chemistry.

The role of metabolism in chemical-induced pulmonary toxicity.

B. R. Smith, W. Brian, Brian R. Smith, 1991, Toxicologic pathology.

Characterization of pulmonary arene oxide biotransformation using the perfused rabbit lung.

J. Plummer, B. R. Smith, L. Ball, 1980, Cancer research.

Metabolism of benzo[a]pyrene by the isolated perfused rabbit lung.

B. R. Smith, J. Bend, R. Philpot, 1978, Drug metabolism and disposition: the biological fate of chemicals.

Selective inhibition of the metabolism of diazinon and diazoxon in vitro by piperonyl butoxide, NIA 16824, and 1-(2-isopropylphenyl)imidazole☆

B. R. Smith, E. Hodgson, W. Dauterman, 1974 .

Metabolism and toxicity of benzo(a)pyrene-4,5-oxide in the isolated perfused rat liver.

B. R. Smith, J. Bend, 1979, Toxicology and applied pharmacology.

Hypoxia-enhanced reduction and covalent binding of [2-3H]misonidazole in the perfused rat liver.

B. R. Smith, Brian R. Smith, 1984, Biochemical pharmacology.

Metabolism and excretion of [3H]misonidazole by hypoxic rat liver.

B. R. Smith, J. Born, 1984, International journal of radiation oncology, biology, physics.

Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

K. Erhard, B. R. Smith, M. Lark, 1999, Journal of Pharmacology and Experimental Therapeutics.

The effect of the recombination-l gene on histidine-5

B. R. Smith, 1967 .

A comparative study of the reaction in vivo and in vitro of rabbit tissues to infection with bovine tubercle bacilli: Part II. Observations on cultures of spleen and lymph glands from infected rabbits

B. R. Smith, E. Brieger, H. Fell, 1951, Epidemiology and Infection.

Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations

K. Ward, B. R. Smith, L. M. Azzarano, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity.

K. Ward, B. R. Smith, M. Levy, 2000, The Journal of pharmacology and experimental therapeutics.

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

B. R. Smith, I. James, M. Miller, 2000, The Journal of clinical investigation.

Improved techniques for semi‐micro synthesis of radioisotope labelled thiophosphate pesticides

B. R. Smith, E. Hodgson, W. Dauterman, 1975 .

The effects of temperature and ionic environment on antagonist binding to cardiac f-adrenoceptors

B. R. Smith, D. Millson, 2007 .